Filtrix Boss (@filtrixboss) header
Filtrix Boss (@filtrixboss) profile picture

❯ CEO of @Filtrix_Net ❯ Don't trade on FOMO. Trade data ❯ You're not a bad trader - you lack data ❯ Not Financial Advice

Joined August 2025
Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)Photo by Filtrix Boss (@filtrixboss)
Twenty-eight times on record, Polar Power has opened at least 5% above its prior close. The median of those sessions closed 1.37% below the open. The mean closed 9.13% above it. Same 28 days, two opposite answers, and the split was 54% closing below the open to 46% above. A mean that far over the median only happens when a few outsized days pay for the rest. The outsized days get remembered. The median day is what a chaser usually gets. $POLA is +42.22% in tonight's after-hours session. The newest article in the feed is from July, announcing a committed equity facility to issue up to $25 million in common stock, on a company whose profile shows a $1M market cap. Whether any of it has been drawn is not in the feed. All of that is this symbol's own history, describing those days only. An after-hours quote is not an opening gap, so tonight is not session twenty-nine.
1
27
Pull Polar Power's 28 sessions with a 5%-plus opening gap on FILTRIX.net?utm_source=x&utm… and set the median open-to-close return next to the mean. Decide which of the two you would actually have been trading.
4
Helus Pharma sent out an invitation on Sunday afternoon. It says the company will present topline results from its Phase 3 APPROACH study of HLP003, an adjunctive treatment in major depressive disorder, on November 16, 2026. That is today, and $HELP is +12.51% before the bell. Read the notice for what it contains. A date. A drug name. A reminder that HLP003 has FDA Breakthrough Therapy Designation, which it already held when the notice went out. What it does not contain is a number from the study, and no later release is in the feed. So the morning's buyers are paying up for the one piece of a Phase 3 that cannot miss its endpoint: the calendar entry.
1
260
For contrast on the same tape: #DRTS is +13.60% with numbers in the release. Interim data from its recurrent glioblastoma trial, eight treated patients all alive at a 6.9-month median follow-up, a 100% objective response rate in the six evaluable. Small and interim, but there is something there to argue with. A calendar entry can't be argued with at all.
1
44
This ticker has too few prior gap-up sessions to compare against anything, and that is worth knowing before the open. Check the sample size on FILTRIX.net?utm_source=x&utm… before a pre-market gap talks you into seeing a pattern.
15
At 12:17 ET one week-ahead post went out under the headline NEXT WEEK COULD GET MESSY. Thirteen minutes before it, another reported that the S&P 500's implied move for the same week had dropped significantly, to 139 points. Both are looking at the same five days. Empire State and the Fed chair on Monday. Retail Sales Tuesday morning and $NVDA earnings Tuesday after the close. FOMC minutes Wednesday. #HD, #TGT and #WMT on the focus list, all inside an OPEX week. Friday's close going in was SPY -0.36% and QQQ -1.20%. I have no tested sample for this lineup, so there is no base rate in this post. What a packed calendar does give you is a deadline for the pre-mortem: one line per open position, written today, with the size, the price where you're wrong, and whether you hold through Tuesday's print or go flat before it. By Friday's close the week will have a realized move to set next to that 139.
1
44
No base rate above because I don't have a tested one for a week like this, and I won't borrow one. If you plan to hold anything through Tuesday's print, build the earnings-gap sample on FILTRIX.net?utm_source=x&utm… first and read how those sessions closed against their own open.
13
Everyone obsesses over what to buy. Almost nobody thinks about how much. Size your positions so that being wrong is boring, not fatal. Boring losses keep you in the game. #PositionSizing #TradingDiscipline
22
Down half the account. Done for the day. Then: "just a small one, just to get back to zero." The market does not know you are down. Only you do. FILTRIX SHOW Episode 1: Rule One. #tradingpsychology #revengetrading #daytrading #tradingdiscipline #stockmarket #trader
44
The loudest bull on the timeline is asking for a trading halt, in a market that never installed a circuit breaker to pull. November average: $75k, last November: $97k. The only halt switch anywhere in this story is on the side of his phone, and he's had it within reach the whole time.
28
Before you trust any close-above-the-open rate, look at what sits underneath it. Pull a setup's historical sessions on FILTRIX.net?utm_source=x&utm… and read the open-to-close moves themselves, not just the headline percentage.
7
Last week our cards went 26/53. Since May 4 our cards went 554/1035. Surface filters alone land close to a coin flip. Dig deeper. Base rates since 2019, not vibes. filtrix.net/digest/2026-W46
1
52
Somebody forgot to tell the stock what the headline said. "SHFS Stock Declines Post Q3 Earnings Despite Loan and Deposit Growth" was published earlier today. Tonight $SHFS is +44.00% in the after-hours session. The quarter underneath both is the same one. Revenue $1.9 million, up 6.5% year over year. Loan program income up 70.2%. Net loss $0.9 million. Ongoing litigation with potential losses up to $7.8 million, which is roughly four quarters of that revenue. The feed has no second article for the reversal. What it has is the profile: a float of 919,166 shares. A report that explained a decline earlier today is sitting under a 44% gain tonight, and nobody edited a word of it.
1
1
538
A +480% earnings surprise is what you get when twenty-four cents is divided by a nickel. VirTra reported $0.19 a share last night against a consensus loss of $0.05, with revenue of $7.62 million topping estimates by 78.12%. $VTSI is +31.30% before the bell on a 10 million share float. Both percentages measure how far off the estimates were. Neither one says whether next quarter looks like this one, and the write-up doesn't say either. If the gap survives to the open, the comparison set is cross-stock, not this ticker's own record: 122 prior before-the-open earnings days with an opening gap up of 30% or more, stocks priced $1 and up. 69% of them closed below that session's open.
4
2
546
#NPCE got a percentage last night too: a loss of $0.03 a share against an expected $0.06, scored as a 50% beat. Revenue was $23.1 million against a $26.9 million estimate, and it is -33.53% before the bell. The surprise figure and the direction of the tape are two separate facts.
1
49
Rebuild that comparison yourself on FILTRIX.net?utm_source=x&utm…: earnings-day opening gaps up of 30% or more, price $1 and up, close measured against the open. Then decide how much a 480% surprise is worth at 9:30.
26
$572,910. That is the market cap on Arcadia Biosciences' profile tonight, written out in full because it fits. $RKDA is -24.31% in the after-hours session after today's 8-K reported results of operations (Item 2.02). The name says biosciences. The industry code on the same profile says crude petroleum and natural gas. The feed doesn't reconcile the two. If you want a bounce stat for the dip: this symbol has 16 prior sessions that opened with a gap down of 5% or more. 56% closed above that session's open, 44% below, median open-to-close +0.28%. Sixteen sessions near a coin flip is a description, not an edge, and an after-hours print isn't an opening gap yet. Which business just reported is answered in the exhibit, not the item number. Until someone reads it, the name and the code are still arguing.
1
78